New document clarifies confusion over hormone therapy for women

June 26, 2008

A new position statement from NAMS provides the latest science on the risks and benefits of hormone therapy for postmenopausal women.

The North American Menopause Society (NAMS) has released updated clinical recommendations for hormone therapy (HT) for postmenopausal women. NAMS claims its latest position statement is based on the most recent evidence in the literature. Entitled “Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society,” the document was developed by an advisory panel of 14 women’s health experts and then approved by the NAMS board. NAMS said that a lot of fear and confusion has surrounded HT recently and its document clears up this confusion.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.